Hyper-CVAD plus nelarabine in the treatment of newly diagnosed patients with T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LL).

6554 Background: Hyper-CVAD achieves high rates of complete remissions (CR) in pts with T-ALL/LL. However, about 50% will relapse. Nelarabine is active in relapsed /refractory T lymphoid malignanci...